MODULATION OF 2'5' OLIGOADENYLATE SYNTHETASE (2,5A)ACTIVITY AND INTERFERON (IFN) BINDING IN PATIENTS (PTS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) UNDERGOING IFN THERAPY

被引：0
|
作者：
ROSENBLUM, MG [1 ]
MAXWELL, BL [1 ]
TALPAZ, M [1 ]
GUTTERMAN, JU [1 ]
机构：
[1] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,HOUSTON,TX 77030
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1984年 / 25卷 / MAR期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：230 / 230
页数：1
相关论文
共 50 条
  • [21] COMBINED MODALITY THERAPY WITH INTENSIVE CHEMOTHERAPY (DOAP) FOLLOWED BY ALPHA-INTERFERON (IFN-A) MAINTENANCE IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
    KANTARJIAN, HM
    TALPAZ, M
    KEATING, MJ
    WALTERS, RS
    MCCREDIE, KB
    FREIREICH, EJ
    GUTTERMAN, JU
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 210 - 210
  • [22] MOLECULAR AND INVITRO STEM-CELL ANALYSIS ON PATIENTS (PTS) WITH CHRONIC MYELOGENEOUS LEUKEMIA (CML) UNDER THERAPY WITH RECOMBINANT INTERFERON-ALFA (IFN ALFA-2B)
    OPALKA, B
    WANDL, U
    KOPPE, J
    MUSS, B
    KLOKE, O
    NIEDERLE, N
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 206 - 206
  • [23] Adjuvant Treatment with Alpha Interferon (IFN) for Patients at High Risk for Relapse after Allogeneic Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
    Bezerra, Evandro Dantas
    Radich, Jerald
    Flowers, Mary E.
    Chielins, Debbie
    Higano, Celestia
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S238 - S238
  • [24] Improvement of cytogenetic response by GM-CSF in chronic myelogenous leukemia (CML) patients previously treated by interferon-alpha (IFN-A) therapy.
    Belhabri, A
    Thiebaut, A
    Thomas, X
    Charrin, C
    Michallet, M
    BLOOD, 2000, 96 (11) : 252B - 253B
  • [25] INTERFERON (IFN)-ALPHA-2 GENOTYPE ANALYSIS OF CHINESE CHRONIC HEPATITIS-B PATIENTS UNDERGOING RECOMBINANT IFN-ALPHA-2A THERAPY
    CROWE, JS
    GEWERT, DR
    BARBER, KA
    LEWIS, AP
    SIMS, MJ
    DAVIES, SL
    SALOM, CL
    WOOD, J
    THOMAS, HC
    THURSZ, M
    LOK, AS
    JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (04): : 875 - 878
  • [26] Simultaneous homoharringtonine (HHT) and interferon alpha (IFN-α) therapy is an effective regimen in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    O'Brien, S
    Kantarjian, H
    Cortes, J
    Giles, FJ
    Beran, M
    Rios, MB
    Mallard, S
    Cheson, B
    Murgo, A
    Talpaz, M
    BLOOD, 1998, 92 (10) : 251A - 251A
  • [27] 2',5'-OLIGOADENYLATE SYNTHETASE-ACTIVITY AS A RESPONSIVE MARKER DURING INTERFERON THERAPY FOR CHRONIC HEPATITIS-C
    GIANNELLI, G
    ANTONELLI, G
    FERA, G
    DIANZANI, F
    SCHIRALDI, O
    JOURNAL OF INTERFERON RESEARCH, 1993, 13 (01): : 57 - 60
  • [28] Absence of influence of prior interferon alfa (IFN alpha) therapy on the outcome of allogeneic bone marrow transplantation (BMT) for chronic myelogenous leukemia (CML).
    Tomas, IF
    Steegman, IL
    Requena, MI
    Soria, VGG
    FernandezRanada, IM
    BLOOD, 1995, 86 (10) : 3859 - 3859
  • [29] PHARMACOKINETIC STUDY OF A HUMAN RECOMBINANT INTERFERON (RE-IFN-ALPHA-A) IN CYNOMOLGUS MONKEYS BY 2'-5' OLIGOADENYLATE SYNTHETASE ASSAY
    BANNAI, H
    TATSUMI, M
    KOHASE, M
    ONISHI, E
    YAMAZAKI, S
    JAPANESE JOURNAL OF MEDICAL SCIENCE & BIOLOGY, 1985, 38 (03): : 113 - 124
  • [30] Retrospective comparison of imatinib versus interferon plus cytarabine (IFN/Ara-c) for chronic myelogenous leukemia (CML) patients in chronic phase (CP).
    Guilhot, F
    Roy, L
    Guilhot, J
    Krahnke, T
    Guerci, A
    Druker, B
    Larson, R
    O'Brien, S
    So, C
    Massimini, G
    BLOOD, 2005, 106 (11) : 52A - 52A
12345